While noninvasive biomarkers for renal fibrosis, such as KIM-1 and EGF, lack specificity or predictive utility for disease progression [7,8], GAS5 emerges as a promising candidate due to its dual regulatory roles in suppressing fibroblast activation and enhancing tubular repair, addressing a critical gap in current clinical practice. Here, GAS5 is linked to renal fibrosis.